Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pretax income is the income that a company earns before paying income taxes. IDEXX Laboratories's pretax income for the
three
months ended in Jun. 2026 was €359 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Jun. 2026 was €1,221 Mil.
IDEXX Laboratories's pretax margin was 34.29%.
During the past 13 years, IDEXX Laboratories's highest Pretax Margin was 31.28%. The lowest was 18.13%. And the median was 25.00%.
During the past 13 years, IDEXX Laboratories's highest Pretax Margin was 31.28%. The lowest was 18.13%. And the median was 25.00%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDEXX Laboratories Pre-Tax Income Related Terms
IDEXX Laboratories Pre-Tax Income Historical Data
* Premium members only.
The historical data trend for IDEXX Laboratories's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, IDEXX Laboratories's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDEXX Laboratories Pre-Tax Income vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where IDEXX Laboratories's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,221 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDEXX Laboratories (FRA:IX1) has a Pre-Tax Income of €1,221 Mil as of Jun. 2026. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on IDEXX Laboratories and its competitors.
Is IDEXX Laboratories' Pre-Tax Income too high?
IDEXX Laboratories' current Pre-Tax Income is €1,221 Mil. Overall, IDEXX Laboratories has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' Pre-Tax Income compare to A and IQV?
IDEXX Laboratories' Pre-Tax Income of €1,221 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Medical Diagnostics & Research company?
A good Pre-Tax Income depends on the Medical Diagnostics & Research industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on IDEXX Laboratories and its competitors. IDEXX Laboratories's current Pre-Tax Income is €1,221 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (FRA:IX1) is currently considered Modestly Undervalued. The stock's GF Value™ is €569.72, compared to a current price of €440.10 — trading 22.8% below its estimated fair value. The current Pre-Tax Income is €1,221 Mil. IDEXX Laboratories' overall GF Score™ is 96/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For IDEXX Laboratories (FRA:IX1), the current Pre-Tax Income is €1,221 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDEXX Laboratories (FRA:IX1) Overvalued in 2026?
Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued.
The current stock price of €440.10 is trading 22.8% below its estimated GF Value™ of €569.72.
GuruFocus considers IDEXX Laboratories to be Modestly Undervalued.
Key valuation signals for FRA:IX1:
Pre-Tax Income: €1,221 Mil
GF Value™: €569.72 vs. price of €440.10 (22.8% below fair value)
No single metric tells the full story. See the FRA:IX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
96GF Score
Get the complete analysis for FRA:IX1
Pre-Tax Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IX1 has been successfully added to your 
